Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RUXOLITINIB Cause Diffuse large b-cell lymphoma? 73 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 73 reports of Diffuse large b-cell lymphoma have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.1% of all adverse event reports for RUXOLITINIB.

73
Reports of Diffuse large b-cell lymphoma with RUXOLITINIB
0.1%
of all RUXOLITINIB reports
26
Deaths
17
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma From RUXOLITINIB?

Of the 73 reports, 26 (35.6%) resulted in death, 17 (23.3%) required hospitalization, and 2 (2.7%) were considered life-threatening.

Is Diffuse large b-cell lymphoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 73 reports have been filed with the FAERS database.

What Other Side Effects Does RUXOLITINIB Cause?

Off label use (12,492) Death (6,561) Fatigue (5,663) Anaemia (3,593) Haemoglobin decreased (3,297) Platelet count decreased (3,028) Diarrhoea (2,531) Asthenia (2,529) Dizziness (2,398) Pneumonia (2,343)

What Other Drugs Cause Diffuse large b-cell lymphoma?

RITUXIMAB (1,571) CYCLOPHOSPHAMIDE (1,183) PREDNISONE (1,062) METHOTREXATE (1,055) VINCRISTINE (1,043) DOXORUBICIN (1,002) LENALIDOMIDE (779) TACROLIMUS (595) DEXAMETHASONE (539) PREDNISOLONE (506)

Which RUXOLITINIB Alternatives Have Lower Diffuse large b-cell lymphoma Risk?

RUXOLITINIB vs SABRIL RUXOLITINIB vs SACCHAROMYCES CEREVISIAE RUXOLITINIB vs SACITUZUMAB GOVITECAN RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY RUXOLITINIB vs SACROSIDASE

Related Pages

RUXOLITINIB Full Profile All Diffuse large b-cell lymphoma Reports All Drugs Causing Diffuse large b-cell lymphoma RUXOLITINIB Demographics